Research integrity risks in health and life sciences

Health and life sciences continue to rapidly emerge as a major sector in Australia’s economy, driving innovation, medical advancement and scientific understanding. As the sector grows, however, it is increasingly exposed to scrutiny around integrity and the consequences that follow when confidence in research and quality is questioned.

These issues were the focus of Bartier Perry’s recent panel discussion, Health and Life Sciences: Research Integrity Under the Microscope, which explored how integrity failures can expose organisations to risk and what practical steps can be taken to reduce that exposure.

The discussion became even more timely following reporting in The Australian concerning the efficacy of a high-profile koala vaccine. Together, the panel and report highlight how disputes about methodology, sample size and data interpretation can quickly escalate into broader questions about trust, governance and accountability.

Why this matters now

As the health and life sciences sector continues to grow, so too does the pressure on organisations to move quickly - whether in securing funding, commercialising research, publishing results or responding to public and stakeholder expectations.

That environment can create heightened risk. Where research findings are later questioned, the impact may extend well beyond the underlying science. Organisations can face scrutiny from regulators, investors, commercial partners, customers and the public.

For organisations in the industry, research integrity is not just an academic or internal governance issue but a potential business risk - that can affect reputation, profitability, stakeholder relationships and market confidence.

What the panel highlighted

Our panel explored how integrity risks arise in practice and how they can translate into legal and commercial exposure. Key themes included:

• liability risks for producers, importers and other organisations relying on third-party results

• the need for robust internal processes for data collection, analysis, validation and oversight

• structural pressures, including funding and publication incentives, that can contribute to overstated outcomes

• the need to balance stronger integrity frameworks against overly burdensome regulation

• the importance of institutional responsibility for independently testing and verifying results.

A consistent theme throughout the discussion was that integrity issues rarely sit in isolation. Once doubts emerge about methodology or interpretation, the consequences can spread quickly, affecting not just the credibility of the research, but also the organisations, individuals and commercial arrangements connected to it.

Klavax

The Australian’s reporting raises concerns regarding Klavax, with earlier claims of significant mortality reduction purportedly being withdrawn following reanalysis of the data, alongside criticisms of the statistical methodology, particularly in attributing survival outcomes to vaccination. While these issues relate to methodology and interpretation rather than safety, they illustrate how research practices and dataset integrity can erode public trust and have significant financial consequences.

Neither the authors nor Bartier Perry in any way allege that the vaccine’s researchers, creators or producers have engaged in misconduct, only that there has been public reporting challenging previously published findings regarding the efficacy of the Klavax vaccine.

What organisations should be thinking about

The Australian’s reporting is a useful reminder for organisations to review whether their internal controls are fit for purpose. That includes considering:

• how research data is collected, analysed and documented

• what validation are in place before findings are published or relied upon

• whether governance structures provide appropriate oversight of scientific claims and communications

• how risks are assessed when relying on third-party research, external experts or collaborative projects

• whether escalation processes are clear when concerns are raised about methodology, interpretation or reporting.

In a high-scrutiny environment, prevention, early detection and independent verification are critical.

Looking ahead

As investment and innovation in the health and life sciences sector continue to accelerate, so too will scrutiny of the research that underpins scientific, regulatory and commercial decision-making.

If your organisation is managing integrity, governance or compliance issues in research-heavy environments, it is important to ensure your frameworks are robust enough to withstand scrutiny.

If you would like further information, please contact our Fraud & Corruption team.

Authors: Gavin Stuart & Zach Bentley

This publication is intended as a source of information only. No reader should act on any matter without first obtaining professional advice.